Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
116
days
European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib
Authors
Francesca Palandri; Elena Rossi; Massimo Breccia; Elena M. Elli; Chiara Sartor; Alessandra Dedola; Alessandra Iurlo; Erika Morsia; Novella Pugliese; Roberto Latagliata; Francesco Mendicino; Alessia Tieghi; Giulia Benevolo; Gianni Binotto; Mirko Farina; Alessandra D’Addio; Mario Tiribelli; Daniela Cilloni; Monica Crugnola; Flavia Salvatore; Filippo Branzanti; Daniele Cattaneo; Fabrizio Cavalca; Emilia Scalzulli; Fabrizio Pane; Francesco Lanza; Florian H. Heidel; Giuseppe A. Palumbo; Valerio De StefanoShow moreShow less
Affiliations
1. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; 2. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy; 3. Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy; 4. Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy; 5. Fondazione IRCCS San Gerardo dei Tintori, Divisione di ematologia e unità trapianto di midollo, Monza, Italy; 6. Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy; 7. Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 8. Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy; 9. Department of Clinical Medicine and Surgery, Hematology Section, University of Naples “Federico II”, Naples, Italy; 10. Hematology Unit, Ospedale Belcolle, Viterbo, Italy; 11. U.O.C. di Ematologia, Department of Hemato-Oncology, Azienda Ospedaliera Annunziata, Cosenza, Italy; 12. Department of Hematology, Azienda USL—IRCCS di Reggio Emilia, Reggio Emilia, Italy; 13. University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy; 14. Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy; 15. Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy; 16. Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy; 17. Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy; 18. Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; 19. Haematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; 20. Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany; 21. Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of Catania, Catania, ItalyShow moreShow less
94
days
Genomic and transcriptomic features associated with responses and outcomes of third-generation tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
Authors
Xiaoshuai Zhang; Lu Yu; Zongru Li; Yazhen Qin; Yueyun Lai; Robert Peter Gale; Xiaojun Huang; Qian JiangShow moreShow less
Affiliations
1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; 2. Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK; 3. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China; 4. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China; 5. Peking University People’s Hospital, Qingdao, ChinaShow moreShow less
133
days
Survival trends in Waldenström macroglobulinemia and comparison of outcomes with the general United States population
Authors
Muhammad Azeem Khan; Gunjan Gaur; Jithma P. Abeykoon; Morie A. Gertz; Shaji Kumar; Rebecca L. King; Jonas Paludo; Thomas M. Habermann; Ronald S. Go; Joselle Cook; Nadine Abdallah; Gita Thanarajasingam; Francis Buadi; Angela Dispenzieri; Carrie A. Thompson; Wilson Gonsalves; Grzegorz S. Nowakowski; David Dingli; Eli Muchtar; Patricia T. Greipp; Surendra Dasari; Joseph Novak; Rahma Warsame; Thomas E. Witzig; S. Vincent Rajkumar; Stephen M. Ansell; Prashant Kapoor; Saurabh ZanwarShow moreShow less
Affiliations
1. Division of Hematology, Mayo Clinic, Rochester, USA; 2. Department of Internal Medicine, Mayo Clinic, Rochester, USA; 3. Division of Hematopathology, Mayo Clinic, Rochester, USA; 4. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USAShow moreShow less
210
days
Differentiation hierarchy in adult B-cell acute lymphoblastic leukemia at clonal resolution
Authors
Alec Geßner; Adrien Jolly; Tjeerd P. Sijmonsma; Yves Matthess; Manuel Kaulich; Hui Ming Tew; Stefan Günther; Fabian Lang; Florian Buettner; Michael A. RiegerShow moreShow less
Affiliations
1. Department of Medicine 2, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany; 2. German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, a partnership between DKFZ and UCT Frankfurt-Marburg, Frankfurt am Main, Germany; 3. German Cancer Research Center (DKFZ), Heidelberg, Germany; 4. Institute of Biochemistry II, Goethe University Frankfurt, Frankfurt am Main, Germany; 5. Cardio-Pulmonary-Institute, Frankfurt am Main, Germany; 6. Frankfurt Cancer Institute, Frankfurt am Main, Germany; 7. Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany; 8. Department of Medicine and Institute of Informatics, Goethe University Frankfurt, Frankfurt am Main, GermanyShow moreShow less
131
days
Mediator kinase inhibition exposes a transcriptional vulnerability and synergizes with venetoclax in AML
Authors
Camille Aitchedji; Céline Moison; Simon Fortier; Rodrigo Mendoza-Sanchez; Deanne Gracias; Jean-François Spinella; Bounkham Thavonekham; Tara MacRae; Nadine Mayotte; Mélanie Fréchette; Valérie Blouin-Chagnon; Koryne Léveillé; Jalila Chagraoui; Réjean Ruel; Josée Hébert; Anne Marinier; Guy SauvageauShow moreShow less
Affiliations
1. Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada; 2. Division d’Hématologie-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, Canada; 3. Banque de Cellules Leucémiques du Québec, Hôpital Maisonneuve-Rosemont, Montréal, Canada; 4. Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada; 5. Department of Chemistry, Université de Montréal, Montréal, CanadaShow moreShow less
501
days
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML
Authors
Ilias Sinanidis; Panagiotis Tsakiroglou; Benjamin Dubner; Rebecca Foertsch; Julia Gondek; InYoung Choi; Bogdan Paun; Teodora Supeanu; Liang Zhao; Gabriel Ghiaur; W. Brian DaltonShow moreShow less
Affiliations
1. Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; 2. Complete Omics Inc, Halethorpe, Baltimore, USAShow moreShow less
FAQ
How long does LEUKEMIA take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for LEUKEMIA. The fastest paper went from submission to acceptance in 41 days (Prof. Richard T Silver—Pioneer of MPN 18 January, 1929–17 April, 2026, received 2026-04-25, accepted 2026-06-05); the slowest took 501 days. The average is 156.3 days and the median is 131 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
